Advicenne S.A. (ALDVI.PA)
EUR 1.71
(-1.72%)
EUR 1.71
(-1.72%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.03 Million EUR | 38.71% |
| 2022 | -11.47 Million EUR | 7.69% |
| 2021 | -12.42 Million EUR | 16.29% |
| 2020 | -14.84 Million EUR | -8.21% |
| 2019 | -13.71 Million EUR | -196.63% |
| 2018 | -4.62 Million EUR | 0.64% |
| 2017 | -4.65 Million EUR | -16.95% |
| 2016 | -3.98 Million EUR | -5.54% |
| 2015 | -3.77 Million EUR | -89.43% |
| 2014 | -1.99 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -2.76 Million EUR | 0.0% |
| 2024 Q1 | -2.76 Million EUR | -67.82% |
| 2023 Q1 | -1.86 Million EUR | 71.95% |
| 2023 Q2 | -3.73 Million EUR | -100.0% |
| 2023 Q3 | -1.64 Million EUR | 55.85% |
| 2023 FY | -7.03 Million EUR | 38.71% |
| 2023 Q4 | -1.64 Million EUR | 0.0% |
| 2022 Q3 | -3.32 Million EUR | 30.84% |
| 2022 Q1 | -2.4 Million EUR | 45.76% |
| 2022 FY | -11.47 Million EUR | 7.69% |
| 2022 Q4 | -6.65 Million EUR | -100.0% |
| 2022 Q2 | -4.81 Million EUR | -100.0% |
| 2021 FY | -12.42 Million EUR | 16.29% |
| 2021 Q4 | -4.43 Million EUR | -100.0% |
| 2021 Q3 | -2.21 Million EUR | 72.23% |
| 2021 Q2 | -7.99 Million EUR | -100.0% |
| 2021 Q1 | -3.99 Million EUR | 44.13% |
| 2020 Q4 | -7.15 Million EUR | -100.0% |
| 2020 Q1 | -3.84 Million EUR | 47.94% |
| 2020 Q3 | -3.57 Million EUR | 53.55% |
| 2020 Q2 | -7.69 Million EUR | -100.0% |
| 2020 FY | -14.84 Million EUR | -8.21% |
| 2019 Q3 | -3.69 Million EUR | 45.69% |
| 2019 Q1 | -3.4 Million EUR | -690.42% |
| 2019 FY | -13.71 Million EUR | -196.63% |
| 2019 Q4 | -7.39 Million EUR | -100.0% |
| 2019 Q2 | -6.8 Million EUR | -100.0% |
| 2018 Q4 | -430.53 Thousand EUR | 0.0% |
| 2018 Q3 | -430.53 Thousand EUR | 77.12% |
| 2018 Q1 | -1.88 Million EUR | -1.43% |
| 2018 Q2 | -1.88 Million EUR | 0.0% |
| 2018 FY | -4.62 Million EUR | 0.64% |
| 2017 Q4 | -1.85 Million EUR | 0.0% |
| 2017 Q2 | -1.16 Million EUR | 0.0% |
| 2017 Q1 | -1.16 Million EUR | -37.39% |
| 2017 FY | -4.65 Million EUR | -16.95% |
| 2017 Q3 | -1.85 Million EUR | -58.79% |
| 2016 FY | -3.98 Million EUR | -5.54% |
| 2016 Q1 | -936.5 Thousand EUR | 0.0% |
| 2016 Q2 | -936.5 Thousand EUR | 0.0% |
| 2016 Q3 | -850.5 Thousand EUR | 9.18% |
| 2016 Q4 | -850.5 Thousand EUR | 0.0% |
| 2015 FY | -3.77 Million EUR | -89.43% |
| 2014 FY | -1.99 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -99.858% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 95.241% |
| Adocia SA | -21.16 Million EUR | 66.775% |
| Aelis Farma SA | -5.07 Million EUR | -38.46% |
| Biophytis S.A. | -17.02 Million EUR | 58.704% |
| genOway Société anonyme | 1.56 Million EUR | 548.527% |
| IntegraGen SA | -171.39 Thousand EUR | -4002.124% |
| Medesis Pharma S.A. | -3.95 Million EUR | -77.573% |
| Neovacs S.A. | -8.74 Million EUR | 19.586% |
| NFL Biosciences SA | -3.74 Million EUR | -87.72% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 8981.001% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -121.732% |
| Sensorion SA | -22.06 Million EUR | 68.133% |
| Theranexus Société Anonyme | -6.82 Million EUR | -2.974% |
| TME Pharma N.V. | -6.73 Million EUR | -4.379% |
| Valbiotis SA | -7.36 Million EUR | 4.574% |
| TheraVet SA | -1.57 Million EUR | -347.633% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 65.439% |
| DBV Technologies S.A. | -67.26 Million EUR | 89.548% |
| Genfit S.A. | -28.89 Million EUR | 75.666% |
| GeNeuro SA | -14.75 Million EUR | 52.355% |
| Innate Pharma S.A. | -7.57 Million EUR | 7.12% |
| Inventiva S.A. | -110.42 Million EUR | 93.633% |
| MaaT Pharma SA | -19.71 Million EUR | 64.34% |
| MedinCell S.A. | -25.03 Million EUR | 71.919% |
| Nanobiotix S.A. | -39.7 Million EUR | 82.29% |
| OSE Immunotherapeutics SA | -23 Million EUR | 69.434% |
| Poxel S.A. | -35.09 Million EUR | 79.963% |
| GenSight Biologics S.A. | -26.22 Million EUR | 73.185% |
| Transgene SA | -22.32 Million EUR | 68.51% |
| Valneva SE | -101.42 Million EUR | 93.068% |